JPMorgan Chase & Co’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-18,500
| Closed | -$29.4K | – | 6675 |
|
|
2024
Q1 | $29.4K | Sell |
18,500
-9,751
| -35% | -$15.5K | ﹤0.01% | 5141 |
|
|
2023
Q4 | $24.3K | Sell |
28,251
-1,385,825
| -98% | -$1.19M | ﹤0.01% | 5203 |
|
|
2023
Q3 | $1.51M | Buy |
1,414,076
+867,199
| +159% | +$928K | ﹤0.01% | 3174 |
|
|
2023
Q2 | $1.42M | Buy |
546,877
+7,015
| +1% | +$18.2K | ﹤0.01% | 3225 |
|
|
2023
Q1 | $2.2M | Sell |
539,862
-26,677
| -5% | -$109K | ﹤0.01% | 2986 |
|
|
2022
Q4 | $2.85M | Buy |
566,539
+32,642
| +6% | +$164K | ﹤0.01% | 2745 |
|
|
2022
Q3 | $6.98M | Sell |
533,897
-18,644
| -3% | -$244K | ﹤0.01% | 2102 |
|
|
2022
Q2 | $7.08M | Buy |
552,541
+18,620
| +3% | +$239K | ﹤0.01% | 2134 |
|
|
2022
Q1 | $8.14M | Sell |
533,921
-88,617
| -14% | -$1.35M | ﹤0.01% | 2204 |
|
|
2021
Q4 | $11M | Sell |
622,538
-4,580
| -0.7% | -$81.1K | ﹤0.01% | 2015 |
|
|
2021
Q3 | $13.2M | Buy |
627,118
+14,245
| +2% | +$299K | ﹤0.01% | 1852 |
|
|
2021
Q2 | $12.1M | Buy |
612,873
+437,541
| +250% | +$8.63M | ﹤0.01% | 2002 |
|
|
2021
Q1 | $5.1M | Sell |
175,332
-16,762
| -9% | -$487K | ﹤0.01% | 2634 |
|
|
2020
Q4 | $5.82M | Sell |
192,094
-10,920
| -5% | -$331K | ﹤0.01% | 2315 |
|
|
2020
Q3 | $3.27M | Sell |
203,014
-15,337
| -7% | -$247K | ﹤0.01% | 2478 |
|
|
2020
Q2 | $4.31M | Sell |
218,351
-25,091
| -10% | -$495K | ﹤0.01% | 2247 |
|
|
2020
Q1 | $3M | Sell |
243,442
-41,823
| -15% | -$516K | ﹤0.01% | 2341 |
|
|
2019
Q4 | $5.27M | Buy |
285,265
+283,025
| +12,635% | +$5.23M | ﹤0.01% | 2138 |
|
|
2019
Q3 | $31K | Buy |
2,240
+393
| +21% | +$5.44K | ﹤0.01% | 4391 |
|
|
2019
Q2 | $27K | Buy |
+1,847
| New | +$27K | ﹤0.01% | 4465 |
|